File Download
There are no files associated with this item.
Links for fulltext
(May Require Subscription)
- Publisher Website: 10.1016/j.ijrobp.2009.12.072
- Scopus: eid_2-s2.0-79952694711
- PMID: 20605357
- WOS: WOS:000288980100020
- Find via
Supplementary
- Citations:
- Appears in Collections:
Article: Can the analysis of ERCC1 expression contribute to individualized therapy in nasopharyngeal carcinoma?
Title | Can the analysis of ERCC1 expression contribute to individualized therapy in nasopharyngeal carcinoma? |
---|---|
Authors | |
Keywords | Predictive ERCC1 Nasopharyngeal carcinoma Prognosis |
Issue Date | 2011 |
Citation | International Journal of Radiation Oncology - Biology - Physics, 2011, v. 79, n. 5, p. 1414-1420 How to Cite? |
Abstract | Purpose: To analyze the expression of excision repair cross-complementation group 1 (ERCC1) protein in predicting the clinical outcome of nasopharyngeal carcinoma (NPC). Methods and Materials: The histologic specimens of 258 patients with Stage III to IVB nonkeratinizing NPC who were treated with radiotherapy alone (Group I) or concurrent-adjuvant chemoradiotherapy (Group II) were retrieved. Immunostaining on ERCC1 protein was performed. The relationship of ERCC1 expression and clinical outcomes was analyzed. Results: The median ERCC1 score (proportion score of positively stained cells times intensity) was 200 (range, 0-300), and ERCC1 expression was defined as high if the score was above the median. In Group I high-score tumor had a statistically lower locoregional failure-free rate (LRFFR) compared with low-score tumor (p < 0.05) but not distant failure-free rate (DFFR) and overall survival (OS). In Group II no statistically differences were noted in LRFFR, DFFR and OS with regard to the ERCC1 expression. Resistance to cisplatin-containing chemotherapy in high-ERCC1 score tumor was not observed in Group II. Interestingly, low-score tumor in Group I achieved similar local and distant control compared with Group II. Multivariate analysis showed that ERCC1 score was an independent prognostic factor in LRFFR (p < 0.05) and approached statistical significance in failure-free survival (p = 0.08) and OS (p = 0.07). Tumor with high ERCC1 score had a 2-fold (95% confidence interval, 1.02-3.85) increased risk of locoregional failure. This may imply an association of ERCC1 expression with the repair of radiation damage. Conclusions: High ERCC1 expression predicts poor locoregional control in NPC. Chemotherapy response is not affected by ERCC1 expression. Further validation is required. © 2011 Elsevier Inc. |
Persistent Identifier | http://hdl.handle.net/10722/213946 |
ISSN | 2023 Impact Factor: 6.4 2023 SCImago Journal Rankings: 1.992 |
ISI Accession Number ID |
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Chan, Siu Hong | - |
dc.contributor.author | Cheung, Florence M F | - |
dc.contributor.author | Ng, Wai Tong | - |
dc.contributor.author | Choi, Cheuk Wai | - |
dc.contributor.author | Cheung, Kin Nam | - |
dc.contributor.author | Yiu, Kwan Ho | - |
dc.contributor.author | Lee, Anne W M | - |
dc.date.accessioned | 2015-08-19T13:41:19Z | - |
dc.date.available | 2015-08-19T13:41:19Z | - |
dc.date.issued | 2011 | - |
dc.identifier.citation | International Journal of Radiation Oncology - Biology - Physics, 2011, v. 79, n. 5, p. 1414-1420 | - |
dc.identifier.issn | 0360-3016 | - |
dc.identifier.uri | http://hdl.handle.net/10722/213946 | - |
dc.description.abstract | Purpose: To analyze the expression of excision repair cross-complementation group 1 (ERCC1) protein in predicting the clinical outcome of nasopharyngeal carcinoma (NPC). Methods and Materials: The histologic specimens of 258 patients with Stage III to IVB nonkeratinizing NPC who were treated with radiotherapy alone (Group I) or concurrent-adjuvant chemoradiotherapy (Group II) were retrieved. Immunostaining on ERCC1 protein was performed. The relationship of ERCC1 expression and clinical outcomes was analyzed. Results: The median ERCC1 score (proportion score of positively stained cells times intensity) was 200 (range, 0-300), and ERCC1 expression was defined as high if the score was above the median. In Group I high-score tumor had a statistically lower locoregional failure-free rate (LRFFR) compared with low-score tumor (p < 0.05) but not distant failure-free rate (DFFR) and overall survival (OS). In Group II no statistically differences were noted in LRFFR, DFFR and OS with regard to the ERCC1 expression. Resistance to cisplatin-containing chemotherapy in high-ERCC1 score tumor was not observed in Group II. Interestingly, low-score tumor in Group I achieved similar local and distant control compared with Group II. Multivariate analysis showed that ERCC1 score was an independent prognostic factor in LRFFR (p < 0.05) and approached statistical significance in failure-free survival (p = 0.08) and OS (p = 0.07). Tumor with high ERCC1 score had a 2-fold (95% confidence interval, 1.02-3.85) increased risk of locoregional failure. This may imply an association of ERCC1 expression with the repair of radiation damage. Conclusions: High ERCC1 expression predicts poor locoregional control in NPC. Chemotherapy response is not affected by ERCC1 expression. Further validation is required. © 2011 Elsevier Inc. | - |
dc.language | eng | - |
dc.relation.ispartof | International Journal of Radiation Oncology - Biology - Physics | - |
dc.subject | Predictive | - |
dc.subject | ERCC1 | - |
dc.subject | Nasopharyngeal carcinoma | - |
dc.subject | Prognosis | - |
dc.title | Can the analysis of ERCC1 expression contribute to individualized therapy in nasopharyngeal carcinoma? | - |
dc.type | Article | - |
dc.description.nature | link_to_subscribed_fulltext | - |
dc.identifier.doi | 10.1016/j.ijrobp.2009.12.072 | - |
dc.identifier.pmid | 20605357 | - |
dc.identifier.scopus | eid_2-s2.0-79952694711 | - |
dc.identifier.hkuros | 266260 | - |
dc.identifier.volume | 79 | - |
dc.identifier.issue | 5 | - |
dc.identifier.spage | 1414 | - |
dc.identifier.epage | 1420 | - |
dc.identifier.isi | WOS:000288980100020 | - |
dc.identifier.issnl | 0360-3016 | - |